Assignee
DEBIOPHARM INT SA
CH·20 granted patents·20 pending applications·31 citations·filing 2013–2024
Top patents by PatentIndex Score
40 records- 0190US11395796B2Anti-CD37 immunoconjugate and anti-CD20 antibody combinationsDEBIOPHARM INT SA·Filed 2018·Granted Jul 26, 2022·5 cites·10 claims
- 0290US10202460B2CD37-binding molecules and immunoconjugates thereofDEBIOPHARM INT SA·Filed 2016·Granted Feb 12, 2019·7 cites·22 claims
- 0389US11466095B2CD37-binding molecules and immunoconjugates thereofDEBIOPHARM INT SA·Filed 2018·Granted Oct 11, 2022·3 cites·21 claims
- 0489US10556958B2CD37-binding molecules and immunoconjugates thereofDEBIOPHARM INT SA·Filed 2016·Granted Feb 11, 2020·7 cites·20 claims
- 0582US12559566B2CD37-binding molecules immunoconjugates thereofDEBIOPHARM INT SA·Filed 2022·Granted Feb 24, 2026·0 cites·20 claims
- 0679US11104740B2Antibodies and assays for detection of CD37DEBIOPHARM INT SA·Filed 2016·Granted Aug 31, 2021·2 cites·19 claims
- 0779US10035813B2Prodrug derivatives of (E)-N-methyl-N-((3-methylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamideDEBIOPHARM INT SA·Filed 2014·Granted Jul 31, 2018·3 cites·27 claims
- 0878US2024280593A1Method for separating target molecules or particles from fibrinogen-containing samples including blood componentsDEBIOPHARM INT SA·Filed 2023·Application pending·0 cites
- 0977US11673140B2Sample collection and processing deviceDEBIOPHARM INT SA·Filed 2020·Granted Jun 13, 2023·1 cites·14 claims
- 1075US12239732B2Anti-CD37 immunoconjugate and anti-CD20 antibody combinationsDEBIOPHARM INT SA·Filed 2022·Granted Mar 4, 2025·0 cites·12 claims
- 1172US11278629B2Methods for improving anti-CD37 immunoconjugate therapyDEBIOPHARM INT SA·Filed 2017·Granted Mar 22, 2022·1 cites·26 claims
- 1272US2025205148A1Slow release pharmaceutical composition made of microparticlesDEBIOPHARM INT SA·Filed 2024·Application pending·0 cites
- 1370US9862737B2Salts, prodrugs and polymorphs of fab I inhibitorsDEBIOPHARM INT SA·Filed 2013·Granted Jan 9, 2018·0 cites·8 claims
- 1466US10751351B2Medicament for treatment of diabetic foot infectionsDEBIOPHARM INT SA·Filed 2017·Granted Aug 25, 2020·2 cites·24 claims
- 1564US2023082575A1Slow release pharmaceutical composition made of microparticlesDEBIOPHARM INT SA·Filed 2022·Application pending·0 cites
- 1664US2021148940A1Method for separating target molecules or particles from fibrinogen-containing samples including blood componentsDEBIOPHARM INT SA·Filed 2021·Application pending·0 cites
- 1763US2020270361A1Cd37-binding molecules and immunoconjugates thereofDEBIOPHARM INT SA·Filed 2020·Application pending·0 cites
- 1862US2024010731A1Combination product for the treatment of cancerDEBIOPHARM INT SA·Filed 2023·Application pending·0 cites
- 1959US2017336424A1Method for separating target molecules or particles from fibrinogen-containing samples including blood componentsDEBIOPHARM INT SA·Filed 2017·Application pending·0 cites
- 2054US2024317740A1Novel compounds and their useDEBIOPHARM INT SA·Filed 2022·Application pending·0 cites
- 2151US2025228780A1Novel compositionDEBIOPHARM INT SA·Filed 2023·Application pending·0 cites
- 2251US2023270893A1Gallium-labeled gastrin analogue and use in a method of imaging cckb-receptor-positive tumors or cancersDEBIOPHARM INT SA·Filed 2021·Application pending·0 cites
- 2351US2022016079A1Combination treatment of hiv infectionsDEBIOPHARM INT SA·Filed 2019·Application pending·0 cites
- 2451US2022347260A1Combination of An Agonist Anti-PD-1 Antibody With a GnRH Agonist or Antagonist to Treat CancerDEBIOPHARM INT SA·Filed 2018·Application pending·0 cites
- 2549US10589275B2Sample collection and processing deviceDEBIOPHARM INT SA·Filed 2015·Granted Mar 17, 2020·0 cites·19 claims
- 2648US2022096436A1Combination product for the treatment of cancerDEBIOPHARM INT SA·Filed 2020·Application pending·0 cites
- 2747US12473283B2Compounds and their useDEBIOPHARM INT SA·Filed 2020·Granted Nov 18, 2025·0 cites·22 claims
- 2846US2021198365A1Combination product for the treatment of cancerDEBIOPHARM INT SA·Filed 2018·Application pending·0 cites
- 2945US2026027117A1Methods of treating small cell lung cancerDEBIOPHARM INT SA·Filed 2023·Application pending·0 cites
- 3044US2021205272A1Dosing regimens for treatment of solid tumors having one or more genetic alterations in fgfr1, fgfr2, and/or fgfr3DEBIOPHARM INT SA·Filed 2019·Application pending·0 cites
- 3144US2025268863A1Dosing regimens for treatment of patients with locally advanced squamous cell carcinomaDEBIOPHARM INT SA·Filed 2020·Application pending·0 cites
- 3243US12403131B2Afabicin formulation, method for making the same and uses thereofDEBIOPHARM INT SA·Filed 2020·Granted Sep 2, 2025·0 cites·18 claims
- 3343US2021093645A1Combination anti cancer therapy with an iap antagonist and an anti pd-1 moleculeDEBIOPHARM INT SA·Filed 2018·Application pending·0 cites
- 3442US12414958B2Medicament and use thereof for treating bacterial infections involving biofilmDEBIOPHARM INT SA·Filed 2020·Granted Sep 16, 2025·0 cites·42 claims
- 3542US9150571B2Crystalline forms of fused amino pyridines as HSP90 inhibitorsDEBIOPHARM INT SA·Filed 2013·Granted Oct 6, 2015·0 cites·22 claims
- 3639US12545672B2Antibiotic compounds, methods of manufacturing the same, pharmaceutical compositions containing the same and uses thereofDEBIOPHARM INT SA·Filed 2019·Granted Feb 10, 2026·0 cites·20 claims
- 3738US2023149504A1Alisporivir for use in human viral infectionsDEBIOPHARM INT SA·Filed 2021·Application pending·0 cites
- 3832US12144818B2Method for treating cancer in a human patient by administering an anti-CD37 immunoconjugate using various dosing regimensDEBIOPHARM INT SA·Filed 2019·Granted Nov 19, 2024·0 cites·20 claims
- 3932US10703798B2Methods of cancer therapy by inhibiting fusion polypeptides comprising fibroblast growth factor receptor 2 (FGFR2) and vinculin (VCL)DEBIOPHARM INT SA·Filed 2015·Granted Jul 7, 2020·0 cites·22 claims
- 4031US2018223371A1Fgfr expression and susceptibility to an fgfr inhibitorDEBIOPHARM INT SA·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when DEBIOPHARM INT SA files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →